A primer on the economics of re-importation of prescription drugs

Using the basic tools of intermediate microeconomic theory (such as taught at the level of undergraduate or first-year MBA courses), in this primer I present a framework that helps the reader gain an understanding of economic issues underlying the current political economy debates concerning the impacts on consumers (both US and ex-US) and on prescription pharmaceutical manufacturers of moving to a world with more uniform pricing across countries than is currently the case. The impact on global revenues and profitability of moving from differential to uniform global pricing is relatively modest if confined to the North American (US and Canadian) market, with only Canadians bearing the brunt of higher prices, a most unlikely political economy outcome. The impacts on global revenues and profitability from global uniform prices become considerably larger, however, when one incorporates the much larger entire ex-US market, including not only Canada, but also Europe, Asia and other countries. I conclude with some observations on likely longer term outcomes. Copyright © 2007 John Wiley & Sons, Ltd.

[1]  Andrew A. Signore,et al.  Pharmaceutical Industry Profile , 2005 .

[2]  J. Vernon,et al.  Pharmaceutical Stock Price Reactions to Price Constraint Threats and Firm-Level R&D Spending , 2005 .

[3]  A. Detsky,et al.  A perspective on US drug reimportation. , 2005, JAMA.

[4]  J. Vernon Examining the link between price regulation and pharmaceutical R&D investment. , 2005, Health economics.

[5]  R. Frank Prescription-drug prices. , 2004, The New England journal of medicine.

[6]  Amy N. Finkelstein Static and Dynamic Effects of Health Policy: Evidence from the Vaccine Industry , 2004 .

[7]  J. Wilson Cheaper Drugs in Foreign Markets Increase the Focus on Domestic Drug Prices , 2004, Annals of Internal Medicine.

[8]  J. Wagner,et al.  International differences in drug prices. , 2004, Annual review of public health.

[9]  Paul A. Saatsoglou Pharmaceutical reimportation: magnitude, trends, and consumers. , 2004, Managed care.

[10]  Michael R. Pakko,et al.  Burgernomics: a big MacT guide to purchasing power parity , 2003 .

[11]  M. Furukawa,et al.  Prices and availability of pharmaceuticals: evidence from nine countries. , 2003, Health affairs.

[12]  Daron Acemoglu,et al.  Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry , 2003 .

[13]  U. Reinhardt,et al.  It's the prices, stupid: why the United States is so different from other countries. , 2003, Health affairs.

[14]  Gerard F Anderson,et al.  Cross-national comparisons of health systems using OECD data, 1999. , 2002, Health affairs.

[15]  E. Berndt Pharmaceuticals in U.S. health care: determinants of quantity and price. , 2002, The journal of economic perspectives : a journal of the American Economic Association.

[16]  F. Scherer,et al.  The link between gross profitability and pharmaceutical R&D spending. , 2001, Health affairs.

[17]  R. Frank Prescription drug prices: why do some pay more than others do? , 2001, Health affairs.

[18]  J. Dumoulin Global pricing strategies for innovative essential drugs , 2001 .

[19]  E. Berndt,et al.  International comparisons of pharmaceutical prices: what do we know, and what does it mean? , 2000, Journal of health economics.

[20]  Henry G. Grabowski,et al.  Effective patent life in pharmaceuticals , 2000, Int. J. Technol. Manag..

[21]  Frank Verboven,et al.  The Evolution of Price Dispersion in the European Car Market , 1998 .

[22]  A. Detsky,et al.  Shopping around for hospital services: a comparison of the United States and Canada. , 1998, JAMA.

[23]  R. Manning Products Liability and Prescription Drug Prices in Canada and the United States1 , 1997, The Journal of Law and Economics.

[24]  D A Redelmeier,et al.  Hospital expenditures in the United States and Canada. , 1993, The New England journal of medicine.

[25]  V. Fuchs,et al.  How does Canada do it? A comparison of expenditures for physicians' services in the United States and Canada. , 1990, The New England journal of medicine.

[26]  H. Varian Chapter 10 Price discrimination , 1989 .